Anika Therapeutics partners with J&J Medtech to distribute Orthovisc and Monovisc in the U.S.

Anika Therapeutics partners with J&J Medtech to distribute Orthovisc and Monovisc in the U.S.
Anika Therapeutics expands U.S. offering

Anika Therapeutics is prioritizing pain treatment for osteoarthritis through its hyaluronic acid-based injection therapies.

The company announced that Orthovisc and Monovisc are available in the U.S. as a result of distribution by J&J Medtech, while Cingal is currently not offered in the U.S. Anika Therapeutics has focused on these therapies for decades to address chronic pain among osteoarthritis patients. The partnership with J&J Medtech expands access to Anika Therapeutics' therapies within the U.S. healthcare market.

Anika Therapeutics recently released a case report on its Integrity implant, which showed superior outcomes in a high-risk rotator cuff patient compared to standard repair. The company has a history of developing therapies targeting musculoskeletal conditions. Previous disclosures have focused on clinical results from innovative products in orthopedics.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.